Mumbai: In a surprise move, Hyderabad-based

孟买：在一项意外的行动中，海得拉巴

Natco Pharma

纳特科制药

and Ahmedabad-based

和艾哈迈达巴德的

Eris Lifesciences

艾丽斯生命科学

are launching their own respective generic semaglutide

正在推出各自版本的通用司美鲁肽

weight-loss injections

减肥注射剂

in both vial and pen-device formats. For convenience of dosing, most companies have relied on selling their brands in the pen device forms.

既有小瓶装也有笔式装置的形式。为了方便剂量，大多数公司都依赖于销售其品牌的笔式装置形式。

The strategy to introduce vials is seen as a masterstroke, enabling the drug makers to offer their brands of injections at an 85% discount to innovator

引入小瓶装的策略被视为妙招，使制药商能够以比创新者低85%的价格提供他们的注射剂品牌。

Novo Nordisk

诺和诺德

's

‘s

semaglutide

司美格鲁肽

molecule that goes off patent on Saturday.

周六专利到期的分子。

The lower-priced vials, expected to retail at ₹1,290-₹1,750 for a month's supply depending on the dosage, are likely to target middle- and lower-income patients, particularly in non-metro markets. The vials will be launched now as patent cliff happens on Saturday, while the pens are expected in April..

预计零售价为 ₹1,290-₹1,750（取决于剂量）的低价小瓶将针对中低收入患者，特别是在非大都市市场。小瓶将于本周六专利悬崖时推出，而注射笔预计将在四月推出。

'This launch significantly improves affordability, bringing effective

“此次发布显著提高了经济性，带来了有效的

GLP-1 therapy

GLP-1治疗

within reach for nearly 70% of India's

近70%的印度人口触手可及

diabetes patient population

糖尿病患者群体

,' said Amit Bakshi, chairman and managing director of Eris Lifesciences.

Amit Bakshi，Eris Lifesciences董事长兼董事总经理表示。

Eris has a third-party manufacturing arrangement with Natco and the brands remain independent, he said. 'The manufacturing will be done in Ahmedabad for all parties involved,' Bakshi told ET. 'We're currently in a partnership with Natco, but as we progress into the second quarter, we will be transitioning towards our own manufacturing and branding,' added Bakshi..

他说，Eris与Natco有第三方制造协议，品牌保持独立。Bakshi告诉《经济时报》：“所有相关方的生产都将在艾哈迈达巴德进行。” Bakshi补充道：“我们目前与Natco是合作伙伴关系，但随着进入第二季度，我们将过渡到自己的生产和品牌。”

Live Events

现场活动

Meanwhile, the pen device, expected to be launched in April, is positioned to compete with leading brands in metropolitan areas. Industry sources said the dual-format rollout mirrors the strategy adopted by Eli Lilly for its weight-loss drug

同时，预计将于四月上市的笔式设备将与一线品牌在大都市地区展开竞争。业内人士表示，这种双形式推出策略与礼来公司为其减肥药采用的战略相似。

Mounjaro

蒙贾罗

(tirzepatide), which is also offered in both vials and prefilled monthly pen, and gives patients flexibility in terms of pricing.

（替西帕肽），也有瓶装和预填充的月用笔，为患者提供了价格上的灵活性。

'While some level of compounding may be required for self-administration of the vials, this approach could be a game-changer,' a senior industry source told ET.

“虽然自行使用小瓶可能需要一定程度的混合，但这种方法可能改变游戏规则，”一位行业资深人士告诉《经济时报》。

The country’s most definitive MSME stage returns on March 24 in New Delhi. Register now for the ET MSME Awards 2025

印度最具权威的中小微企业盛会将于3月24日在新德里回归。立即注册参加2025年《经济时报》中小微企业奖。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)